Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumab

descriptionPublicationkeyboard_double_arrow_right Article 30 Mar 2023 English Publisher:Oxford University Press (OUP)Journal:Clinical and Experimental Dermatology, volume 48, pages 929-941 (issn: 0307-6938, eissn: 1365-2230,

Copyright policy )

Authors: Shun, Ohmori; Yu, Sawada;

doi: 10.1093/ced/llad119

pmid: 36994894

Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumab

- Summary
- Subjects
- Metrics

Abstract

We present a case of perforating dermatosis in a patient with uraemic pruritus who was on haemodialysis and who was successfully treated with nemolizumab, a humanized monoclonal antibody targeted against interleukin-31 receptor A. Nemolizumab may be a treatment option for perforating dermatosis with a uraemic pruritus background. To our knowledge, this is the first report to show the effect of nemolizumab on perforating dermatosis.

Related Organizations

University of Occupational and Environmental Health Japan
Japan

Keywords

Renal Dialysis, Humans, Antibodies, Monoclonal, Humanized, Skin Diseases

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%